Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma
Journal
Journal of Medical Virology
Journal Volume
85
Journal Issue
3
Pages
524-529
Date Issued
2013
Author(s)
Chang C
Middeldorp J
Yu K.J
Juwana H
Hsu W.-L
Chen J.-Y
Liu M.-Y
Pfeiffer R.M
Chen C.-J
Hildesheim A.
Abstract
Epstein-Barr virus (EBV) infection is associated with undifferentiated nasopharyngeal carcinomas (NPC). A distinct seroreactivity pattern to EBV is predictive of subsequent risk of sporadic and familial nasopharyngeal carcinomas. There are currently no accepted screening tools for guiding the clinical management of individuals at high-risk for nasopharyngeal carcinomas, particularly unaffected relatives from nasopharyngeal carcinoma multiplex families. Therefore, the reproducibility of a panel of largely synthetic peptide-based anti-EBV antibody ELISAs was evaluated and their ability to distinguish nasopharyngeal carcinoma cases from controls was explored. IgG and IgA antibodies against 6 different EBV antigens (10 assays, total) were tested on sera from 97 individuals representing the full spectrum of anti-EBV seroprevalence (i.e., healthy individuals with no known EBV seroreactivity, healthy individuals with known EBV seroreactivity, and nasopharyngeal carcinoma cases). Each specimen was tested in triplicate to assess within-batch and across-batch variation, and the triplicate testing was repeated on two separate days. Reproducibility was assessed by the coefficients of variation (CVs) and intraclass correlation coefficients (ICCs). All markers were detectable in 17% or more of samples. For all but one marker, the overall, within-batch, and across-batch CVs were below 15%, and the ICCs were above 70% for all but three markers. Sensitivity of these markers to detect prevalent nasopharyngeal carcinomas ranged from 22% to 100%, and among unaffected controls, most distinguished those with and without known seropositivity. In conclusion, a large number of EBV markers can be measured reliably in serum samples using peptide-based anti-EBV ELISAs. J. Med. Virol. 85:524-529, 2013. Puiblished 2012. This is a US government work, and, as such, is in the public domain of The United States of America. Puiblished 2012. This is a US government work, and, as such, is in the public domain of The United States of America..
SDGs
Other Subjects
epstein barr virus antibody; immunoglobulin A; immunoglobulin A antibody; unclassified drug; virus antibody; article; controlled study; disease association; enzyme linked immunosorbent assay; human; major clinical study; nasopharynx carcinoma; reproducibility; sensitivity and specificity; Antibodies, Viral; Antigens, Viral; Clinical Laboratory Techniques; Enzyme-Linked Immunosorbent Assay; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunoglobulin A; Immunoglobulin G; Nasopharyngeal Neoplasms; Sensitivity and Specificity
Type
journal article